Status:
COMPLETED
Ability Of ([18F]-AV-45) PET Scan to Distinguish Alzheimer's Disease Subjects From Cognitively Normal Individuals
Lead Sponsor:
Avid Radiopharmaceuticals
Collaborating Sponsors:
American College of Radiology Imaging Network
General Electric
Conditions:
Alzheimer's Disease
Eligibility:
All Genders
55-90 years
Phase:
PHASE2
Brief Summary
This study will evaluate the performance characteristics of a novel \[18F\] amyloid detection ligand (18F\]-AV-45) with respect to its ability to distinguish patients with clinically-diagnosed probabl...
Detailed Description
15 patients with a clinical diagnosis of probable Alzheimer's disease and 15 cognitively normal elderly control subjects will receive both \[18F\]-AV-45 and \[11C\]PIB to compare the diagnostic perfor...
Eligibility Criteria
Inclusion
- Normal subjects: mini-mental state examination (MMSE) 27-30, clinical dementia rating (CDR) = 0, no symptoms of depression
- Alzheimer's subjects: MMSE 18-26, CDR \>=0.5, University of Pennsylvania Alzheimer's Disease Center consensus diagnosis of probable AD, absence of abnormalities on MRI
Exclusion
- other neurological disease
- evidence of MRI abnormality
- psychiatric disorder
- alcohol abuse
- clinically significant lab abnormalities
- residence in nursing facility
- participation in clinical trial with experimental medication in past 1 month
Key Trial Info
Start Date :
March 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2011
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT00855868
Start Date
March 1 2009
End Date
January 1 2011
Last Update
July 26 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Philadelphia, Pennsylvania, United States, 19104